SC 13D
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
MARSHALL EDWARDS, INC.
(Name of Issuer)
Common Stock, par value $0.00000002 per share
(Title of Class of Securities)
572322303
(CUSIP Number)
David Seaton
Chief Financial Officer
Novogen Limited
140 Wicks Road
North Ryde, NSW 2113
Australia
(011) 61-2-8877-6196
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
July 28, 2008
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the
acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule
13d-1(e), 13d-1(f) or 13d-1(g), check the following box. o
|
|
|
|
|
|
1 |
|
NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Novogen Limited EIN: |
|
|
|
|
|
|
2 |
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
|
|
(a) o |
|
(b) o |
|
|
|
3 |
|
SEC USE ONLY |
|
|
|
|
|
|
|
4 |
|
SOURCE OF FUNDS |
|
|
|
WC |
|
|
|
5 |
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e) |
|
|
|
o |
|
|
|
6 |
|
CITIZENSHIP OR PLACE OF ORGANIZATION |
|
|
|
Novogen Limited is organized under the laws of Australia
|
|
|
|
|
|
7 |
|
SOLE VOTING POWER |
|
|
|
NUMBER OF |
|
52,408,295 |
|
|
|
|
SHARES |
8 |
|
SHARED VOTING POWER |
BENEFICIALLY |
|
|
OWNED BY |
|
0 |
|
|
|
|
EACH |
9 |
|
SOLE DISPOSITIVE POWER |
REPORTING |
|
|
PERSON |
|
52,408,295 |
|
|
|
|
WITH |
10 |
|
SHARED DISPOSITIVE POWER |
|
|
|
|
|
0 |
|
|
|
11 |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON |
|
|
|
52,408,295 |
|
|
|
12 |
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES |
|
|
|
o
|
|
|
|
13 |
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) |
|
|
|
71.3% |
|
|
|
14 |
|
TYPE OF REPORTING PERSON |
|
|
|
CO |
Item 1. Security and Issuer
This Schedule 13D relates to the common stock, par value $0.00000002 per share (Common
Stock), of Marshall Edwards, Inc., a corporation organized under the laws of the State of Delaware
(the Company). The principal executive office of the Company is located at 140 Wicks Road, North
Ryde NSW 2113, Australia. Information given in response to each item below shall be deemed
incorporated by reference in all other items below.
Item 2. Identity and Background
(a) This Schedule 13D is being filed by Novogen Limited. (Novogen).
(b) The principal business address and principal office address of Novogen is 140 Wicks Road,
North Ryde NSW 2113, Australia. Novogen is biotechnology company specializing in the development
of therapeutics based on a flavonoid technology platform.
(c) Attached as Schedule A is the name, principal occupation, business address and citizenship
of each executive officer and/or director of Novogen. Schedule A is incorporated into and made a
part of this Schedule 13D.
(d) During the last five years, neither Novogen nor any person listed on Schedule A has been
convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) During the last five years, neither Novogen nor any person listed on Schedule A has been a
party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a
result of such proceeding was or is subject to a judgment, decree or final order enjoining future
violations of, or prohibiting or mandating activities subject to, federal or state securities laws
or finding any violation with respect to such laws.
(f) Novogen is organized under the laws of Australia. Schedule A sets forth the citizenship
of each executive officer and/or director of Novogen.
Item 3. Source and Amount of Funds or Other Consideration
Novogen utilized available cash assets to acquire beneficial ownership of the 52,408,295
shares of Common Stock reported herein. Funds for the purchase of beneficial ownership of such
shares of Common Stock were derived from general working capital
Item 4. Purposes of Transactions
The Company was formed as a wholly-owned subsidiary of Novogen in 2000.
In May 2002, the Company sold 2,523,000 shares of Common Stock and warrants exercisable for
2,523,000 shares of Common Stock in a private placement. Following the sale, Novogen held 95.1% of
the Companys outstanding shares of Common Stock.
In December 2003, the Company consummated its initial public offering (the IPO) in the U.S.
selling 2,392,000 shares of Common Stock and warrants exercisable for 2,392,000 shares of Common
Stock. Following the IPO, Novogen held 86.9% of the Companys outstanding shares of Common Stock.
In July 2006, the Company consummated a private placement selling 6,329,311 shares of
Common Stock and warrants exercisable for 2,215,258 shares of Common Stock. Following this
placement, Novogen held 78.1% of the Companys outstanding shares of Common Stock.
In August 2007, the Company consummated a second private placement selling 5,464,001 shares of
Common Stock and warrants exercisable for 2,433,962 shares of Common Stock. Following this
placement, Novogen held 71.9% of the Companys outstanding shares of Common Stock.
As described in Item 5(c) of this Schedule 13D, on July 28, 2008, Novogen purchased 2,908,295
shares of Common Stock from the Company in a registered direct offering at a purchase price of
$2.17 per share for an aggregate purchase price of $6,311,000. Novogen entered into the foregoing
transaction to acquire shares of the Companys Common Stock for investment purposes. Concurrently
with the sale to Novogen, the Company sold 1,700,000 shares of Common Stock to another investor in
a registered direct offering. Following these two transactions, Novogen held 71.3% of the
Companys outstanding shares of Common Stock.
At this time, none of Novogen or, to its knowledge, any of its respective directors or
executive officers have plans to acquire or dispose of the Companys securities. At this time,
none of Novogen or, to its knowledge, any of its respective directors or executive officers, have
plans or proposals to implement any plans or proposals with respect to any material change of the
Companys business or corporate structure or, generally, any other action referred to in
instructions (a) through (j) of Item 4 to Schedule 13D.
Novogen retains the right to change its investment intent, from time to time, to acquire
additional shares of Common Stock, or to sell or otherwise dispose of all or part of the Common
Stock, if any, beneficially owned by it, in any manner permitted by law.
Item 5. Interest in Securities of the Issuer
(a) As of the date hereof, Novogen is the beneficial owner of 52,408,295 shares of Common
Stock which constitutes approximately 71.3% of the Companys 73,463,233 issued and outstanding
shares of Common Stock.
(b) Novogen has the sole power to vote or direct the vote and the sole power to dispose or
direct the disposition of all of the shares reported above in this Item 5.
(c) On July 28, 2008, Novogen purchased 2,908,295 additional shares of Common Stock from the
Company in a registered direct offering at a purchase price of $2.17 per share for an aggregate
purchase price of $6,311,000.
(d) No other person is known to have the right to receive or the power to direct the receipt
of dividends from, or the proceeds from the sale of, the Common Stock beneficially owned by
Novogen.
(e) Not applicable
|
|
|
Item 6.
|
|
Contracts, Arrangements, Understandings or Relationships with Respect to Securities of Issuer |
|
|
|
|
|
None |
|
|
|
Item 7.
|
|
Material to Be Filed as Exhibits |
|
|
|
|
|
None |
SIGNATURE
After reasonable inquiry and to the best of the knowledge and belief of each of the
undersigned, each of the undersigned certifies that the information set forth in this statement is
true, complete and correct.
Dated: August 7, 2008
|
|
|
|
|
|
NOVOGEN LIMITED
|
|
|
By: |
/s/
David R. Seaton |
|
|
|
Name: |
David R. Seaton |
|
|
|
Title: |
Chief Financial Officer |
|
|
SCHEDULE A
Novogen Limited
Directors
|
|
|
|
|
|
|
|
|
Name |
|
Position |
|
Principal Occupation |
|
Business Address |
|
Citizenship |
Philip A. Johnston
|
|
Non-Executive
|
|
Managing Director, Qualcare
|
|
Maderty River Road
|
|
Australia |
|
|
Chairman of the Board
|
|
Management Pty. Ltd.
|
|
Coonabarabran NSW |
|
|
|
|
of Directors
|
|
|
|
2357 |
|
|
|
|
|
|
|
|
Australia |
|
|
|
|
|
|
|
|
|
|
|
Christopher Naughton
|
|
Managing Director
|
|
Managing Director, Novogen Limited
|
|
140 Wicks Road North Ryde, NSW 2113 Australia
|
|
Australia |
|
|
|
|
|
|
|
|
|
Paul J. Nestel
|
|
Non-Executive Director
|
|
Medical Practitioner, Baker Heart
|
|
75 Commercial Rd
|
|
Australia |
|
|
|
|
Research Institute
|
|
Melbourne, VIC 3004, |
|
|
|
|
|
|
|
|
Australia |
|
|
|
|
|
|
|
|
|
|
|
Peter B. Simpson
|
|
Non-Executive Director
|
|
Chairman, Biogenerics Australia
|
|
10 Monomeath Avenue
|
|
Australia |
|
|
|
|
Pty Ltd.
|
|
Canterberry |
|
|
|
|
|
|
|
|
Victoria 3126 |
|
|
|
|
|
|
|
|
Australia |
|
|
|
Geoffrey M. Leppinus
|
|
Non-Executive Director
|
|
Former Senior Audit and Advisory
|
|
20 B Ayres Road
|
|
Australia |
|
|
|
|
Partner, KPMG
|
|
St. Ives NSW 2075 |
|
|
|
|
|
|
|
|
Australia |
|
|
|
|
|
|
|
|
|
|
|
Alan J. Husband
|
|
Executive Director
|
|
Director of Research of Novogen
|
|
140 Wicks Road
|
|
Australia |
|
|
|
|
Limited
|
|
North Ryde, NSW 2113 |
|
|
|
|
|
|
|
|
Australia |
|
|
Executive Officers
|
|
|
|
|
|
|
Name |
|
Position |
|
Business Address |
|
Citizenship |
David R. Seaton
|
|
Chief Financial Officer
|
|
140 Wicks Road
|
|
Australia |
|
|
|
|
North Ryde, NSW 2113 |
|
|
|
|
|
|
Australia |
|
|
|
|
|
|
|
|
|
Warren Lancaster
|
|
Vice President Commercial
|
|
59 Grove Street, Suite 2i
|
|
Australia |
|
|
and Corporate Development
|
|
New Canaan, CT 06840 |
|
|
|
|
|
|
|
|
|
Bryan Palmer
|
|
Operations General Manager
|
|
140 Wicks Road
|
|
Australia |
|
|
|
|
North Ryde, NSW 2113 |
|
|
|
|
|
|
Australia |
|
|
|
|
|
|
|
|
|
Craig Kearney
|
|
General Manager Consumer
Business
|
|
140 Wicks Road
North Ryde, NSW 2113
Australia
|
|
Australia |
|
|
|
|
|
|
|
Ron Erratt
|
|
Company Secretary
|
|
140 Wicks Road |
|
Australia |
|
|
|
|
North Ryde, NSW 2113 |
|
|
|
|
|
|
Australia |
|
|